Dahlager J I
Scand J Infect Dis Suppl. 1980;Suppl 23:96-102.
The antibiotics of the aminoglycoside group are all potentially nephrotoxic. Aminoglycosides are exclusively excreted via the kidneys by glomerular filtration. On passing the proximal tubular cells of the nephron, an active reabsorption and intracellular concentration, 10-20 times the serum concentration, take place. Aminoglycosides are trapped in the lysozymes and inhibit cell metabolism. Functional changes are at first discrete, comprising polyuria, slight proteinuria, enzymuria and glycosuria. With more progressive changes the glomerular filtration rate decreases, followed by increased blood urea and serum-creatinine. The urine contains protein, casts and shedded tubular cells. Ultimately, but rarely, oligo-anuric renal failure may be encountered. Compared with gentamicin, the newer aminoglycosides, amikacin, tobramycin and netilmicin show in animal experiments a decreasing nephrotoxicity in the mentioned order. Extensive studies have demonstrated that netilmicin may be the drug with the least nephrotoxic potential. Clinical studies confirm that netilmicin is less nephrotoxic than gentamicin and compares favourably with tobramycin and amikacin. A survey of the literature is given.
氨基糖苷类抗生素都有潜在的肾毒性。氨基糖苷类药物完全通过肾小球滤过经肾脏排泄。当通过肾单位的近端肾小管细胞时,会发生主动重吸收和细胞内浓缩,细胞内浓度可达血清浓度的10 - 20倍。氨基糖苷类药物被困在溶酶体中并抑制细胞代谢。起初功能变化不明显,包括多尿、轻度蛋白尿、酶尿和糖尿。随着病情进展,肾小球滤过率降低,随后血尿素和血清肌酐升高。尿液中含有蛋白质、管型和脱落的肾小管细胞。最终,但很少见,可能会出现少尿 - 无尿性肾衰竭。与庆大霉素相比,新型氨基糖苷类药物阿米卡星、妥布霉素和奈替米星在动物实验中按上述顺序显示出肾毒性逐渐降低。广泛的研究表明,奈替米星可能是肾毒性潜力最小的药物。临床研究证实,奈替米星的肾毒性低于庆大霉素,与妥布霉素和阿米卡星相比也更具优势。现给出文献综述。